Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Role of neoadjuvant chemoimmunotherapy for resectable NSCLC

Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. (2022).

    Article  PubMed  Google Scholar 

  2. Jiang, J. et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl. Lung Cancer Res. 11, 277–294 (2022).

    Article  CAS  Google Scholar 

  3. Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021).

    Article  CAS  Google Scholar 

  4. Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020).

    Article  CAS  Google Scholar 

  5. Pisters, K. M. et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 28, 1843–1849 (2010).

    Article  CAS  Google Scholar 

  6. Hellmann, M. D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42–e50 (2014).

    Article  CAS  Google Scholar 

  7. Testing new neoadjuvant combos in NSCLC. Cancer Discov. OF1 (2022).

Download references


The authors thank T. Cascone (The University of Texas MD Anderson Cancer Center) for her expertise and consultation regarding this article.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Boris Sepesi.

Ethics declarations

Competing interests

B.S. has received speaker’s fees from AstraZeneca and Peer View, and consultation fees from AstraZeneca and Medscape. S.S. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sepesi, B., Swisher, S.G. Role of neoadjuvant chemoimmunotherapy for resectable NSCLC. Nat Rev Clin Oncol 19, 497–498 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer